Beautyskin Reports Continued Operating Loss in Q1 2026 and Increased Debt Ratio

Consolidated Q1 2026 revenue KRW 12.5B, down 33% YoY from KRW 18.7B
Consolidated operating loss KRW 1.48B, net loss KRW 2.03B
In January 2026, executed 1:3 stock dividend (10,602,117 new shares; total shares 14.1M, par value KRW 500)
Consolidated debt ratio 191.33% (up from 168.17% at year-end 2025)
Equity KRW 31B, retained earnings -KRW 4.05B (deficit)
New subsidiary (Pesel) added (health supplements; revenue KRW 4.04B)
Ongoing embezzlement lawsuit (KRW 5.4B) related to former subsidiary Wonjin W&R; outcome uncertain
Credit rating BB- (NICE, as of April 2025)
Loss allowance for trade receivables over 1 year: 58.17%